You are here
European drugmakers Sanofi and GSK strike $2.1 billion deal with U.S. for a coronavirus vaccine
Primary tabs
The first human testing of the experimental vaccine is expected to begin in September, with larger trials to test its effectiveness due to launch before year’s end. The companies anticipate having enough data to seek a regulatory decision in the first half of 2021 and plan to manufacture 1 billion doses per year.
The contract, which includes the option for the United States to buy an additional 500 million doses, includes support for clinical development of the vaccine and an advance purchase agreement. The U.S. government has committed billions of dollars to companies to lessen the financial risks of manufacturing vaccines before drugmakers know whether they work.
“The portfolio of vaccines being assembled for Operation Warp Speed increases the odds that we will have at least one safe, effective vaccine as soon as the end of this year,” Health and Human Services Secretary Alex Azar said in a statement.
The United States also has spent billions of dollars to support the development of vaccines, or the pre-purchasing of doses, from Johnson & Johnson, Moderna, Novavax, Pfizer and AstraZeneca.
Recent Comments